AstraZeneca’s stock has been rising for two weeks on growing expectations the British pharmaceutical firm will re-engage in merger negotiations with Pfizer after the partial expiration of a cooling-off period.

JOHNSON & Johnson has announced plans to eliminate 3-4% of its global workforce of about 120,500 people as part of an effort to improve its cost structure.